Abstract: The present invention is based on the discovery of a two- or three-organism model system that can be used to identify virulence factors involved in fungal infection and to screen for agents that attenuate the activity of those factors. The system includes a model eukaryote, the nematode, Caenorhabditis elegans, and one or more species of Candida, a fungal pathogen that infects humans, e.g., Candida albicans, C. dubliniensis, C. krusei, C. tropicalis, C. parapsilosis, or C. glabrata. The system also includes a food source for the C. elegans; the food source can be a live or attenuated bacterium, e.g., Escherichia coli.
Abstract: The invention relates to a non-human transgenic mammal with an IgH locus modified by replacement of the switching sequence S? with all or part of a transgene comprising the gene C? of a class A human immunoglobulin, including at least the exon, coding for the CH3 domain and the membrane exon and the applications of the above for the production of humanized class IgA antibodies.
Type:
Grant
Filed:
October 21, 2004
Date of Patent:
January 14, 2014
Assignees:
Centre National de la Recherche Scientifique, Universite de Limoges
Inventors:
Michel Cogne, Christophe Sirac, Micael Bardel, Catherine Decourt, Caroline Le Morvan
Abstract: The present invention relates to transgenic non-human animals, tissues or cells derived therefrom and methods of producing them. The transgenic non-human animals or tissues or cells derived therefrom provide a system capable of expressing human proteins responsible for drug metabolism in place of the homologous endogenous non-human animal proteins and for the controlled expression of human genes introduced into the animal so that the expression of the human genes is regulated in a manner more closely analogous to that seen in vivo in humans. One aspect of the invention relates to the use of a human DNA sequence comprising at least part of introns 6 and/or 7 of the human PXR gene.
Abstract: A mouse model in which human fetal thymus and human fetal bone fragments are transplanted into NSG mice, a method of producing the same, and a use thereof.
Type:
Grant
Filed:
September 7, 2011
Date of Patent:
December 10, 2013
Assignee:
Samsung Life Welfare Foundation
Inventors:
Sung Joo Kim, Yun Shin Chung, Sung Yeon Joo, Bong Kim Choi, Jae Won Joh
Abstract: This invention relates to the field of biotechnology or genetic engineering. Specifically, this invention relates to the field of gene expression. More specifically, this invention relates to a novel ecdysone receptor/chimeric retinoid X receptor-based inducible gene expression system and methods of modulating gene expression in a host cell for applications such as gene therapy, large-scale production of proteins and antibodies, cell-based high throughput screening assays, functional genomics and regulation of traits in transgenic organisms.
Type:
Grant
Filed:
August 24, 2007
Date of Patent:
December 3, 2013
Assignee:
Intrexon Corporation
Inventors:
Marianna Zinovievna Kapitskaya, Subba Reddy Palli
Abstract: An object of the present invention is to provide a method for introducing a gene into an embryo for production of a human disease model primate animal using a non-human primate animal such as a marmoset. The present invention relates to a method for introducing a foreign gene into an early embryo of a non-human primate animal, which comprises placing early embryos of a non-human primate in a 0.2 M to 0.3 M sucrose solution, so as to increase the volume of the perivitelline spaces, and then injecting a viral vector containing a human foreign gene operably linked to a promoter into the perivitelline spaces of the early embryos.
Type:
Grant
Filed:
December 9, 2008
Date of Patent:
November 26, 2013
Assignees:
Central Institute for Experimental Animals, Keio University
Abstract: The present invention relates to methods for producing a non human animal model for aortic aneurysm which could provide insight into the diagnosis and treatment of disease. Furthermore, the present invention relates to methods and compositions for the treatment or the prevention of aneurysm in a subject in need thereof.
Type:
Grant
Filed:
September 30, 2008
Date of Patent:
November 19, 2013
Assignee:
INSERM (Institut National de la Sante et de la Recherche Medicale)
Inventors:
Pierre Louis Tharaux, Hafid Ait-Oufella, Alain Tedgui, Ziad Mallat
Abstract: The present invention relates to a nucleus covered or coated with a film including one or more PHA. The invention also relates to a PHA, characterized in that it is of the type PHB-V, a film and a composition including the PHA. The invention further relates to a film or a composition including a PHA and zosteric acid or a bioactive molecule. The invention moreover relates to a surface, preferably a nucleus, covered with the film of PHA, a method for production thereof, and methods for grafting a pearl oyster and producing a pearl using this nucleus. Finally, the present invention relates to a method for reducing graft failure and/or for improving the quality of the pearl using the nucleus according to the invention.
Type:
Application
Filed:
December 14, 2011
Publication date:
October 10, 2013
Applicant:
DIRECTION DES RESSOURCES MARINES
Inventors:
Jean Guezennec, Christelle Simon-Colin, Achraf Kouzayha, Evelyne Bachere
Abstract: The present invention provides novel methods of maintaining genetic stability of non-human animal inbred strains. In the methods, pedigree-tracked cryopreserved embryos or gametes or pre-gametes derived from a foundation colony are produced and used to re-establish the foundation colony at appropriate intervals.
Type:
Grant
Filed:
October 26, 2009
Date of Patent:
October 8, 2013
Assignee:
The Jackson Laboratory
Inventors:
Michael V. Wiles, Robert Taft, Eva M. Eicher, Shannon Byers
Abstract: A formulation and method for insect control is provided in the form of insecticide carrying insects which can be introduced in a population to thereby control the insect population. The formulation may include artificially generated adult insect carriers of a larvicide in which the larvicide has minimal impact on the adult insect and which larvicide affects juvenile survival or interferes with metamorphosis of juvenile insects to adulthood. The insects may be either male or female and may include mosquitoes.
Abstract: A method for predicting risk of joint dysplasia, osteoarthritis and/or a condition that is secondary to joint dysplasia in a mammalian subject of the order Carnivora, the method comprising: (a) determining the genotype of said subject in respect of one or more genetic polymorphisms and/or alterations, such as polymorphisms in the CHST3 gene; and (b) providing a prediction of said risk based on said genotype. Products for use in such a method and related methods of determining propensity of a subject to respond to therapy and of selective breeding, are also disclosed.
Inventors:
Antonio Martinez, Laureano Simon, Diego Tejedor, Marta Artieda, Nerea Bartolome, Jose Escaich, Alfonso Velasco, Miriam Selles, Carlos Chetrit, Daniel Martinez, Armand Sanchez, Olga Francino, Elisenda Sanchez
Abstract: The present invention relates to a glioma stem cell population, wherein the glioma stem cells do not present a telomerase activity and to a method for obtaining such cells.
Type:
Application
Filed:
August 11, 2011
Publication date:
October 3, 2013
Applicants:
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES
Inventors:
François Boussin, David Silvestre, Hervé Chneiweiss, Marie-Pierre Junier
Abstract: The present invention relates to a genetically modified pig as a model for studying atherosclerosis. The modified pig model displays one or more phenotypes associated with atherosclerosis. Disclosed is also a modified pig comprising a mutation in the endogenous ApoE gene or part thereof, LDL gene or part thereof, LDL receptor gene, or transcriptional or translational product or part thereof. The invention further relates to methods for producing the modified pig; and methods for evaluating the effect of a therapeutical treatment of atherosclerosis; methods for screening the efficacy of a pharmaceutical composition; and a method for treatment of a human being suffering from atherosclerosis are disclosed.
Type:
Grant
Filed:
March 6, 2008
Date of Patent:
October 1, 2013
Assignee:
Aarhus Universitet
Inventors:
Jacob Fog Bentzon, Charlotte Brandt Sørensen, Peter Michael Kragh, Jacob Giehm Mikkelsen, Erling Falk, Lars Axel Bolund, Thomas Juhl Corydon
Abstract: The present invention provides an immunodeficient mouse (NOG mouse) suitable for engraftment, differentiation and proliferation of heterologous cells, and a method of producing such a mouse. This mouse is obtained by backcrossing a C.B-17-scid mouse with an NOD/Shi mouse, and further backcrossing an interleukin 2-receptor ?-chain gene-knockout mouse with the thus backcrossed mouse. It is usable for producing a human antibody and establishing a stem cell assay system, a tumor model and a virus-infection model.
Type:
Grant
Filed:
November 17, 2009
Date of Patent:
September 24, 2013
Assignee:
Central Institute for Experimental Animals
Abstract: A mouse with a humanization of the mIL-3 gene and the mGM-CSF gene, a knockout of a mRAG gene, and a knockout of a mIl2rg subunit gene; and optionally a humanization of the TPO gene is described. A RAG/Il2rg KO/hTPO knock-in mouse is described. A mouse engrafted with human hematopoietic stem cells (HSCs) that maintains a human immune cell (HIC) population derived from the HSCs and that is infectable by a human pathogen, e.g., S. typhi or M. tuberculosis is described. A mouse that models a human pathogen infection that is poorly modeled in mice is described, e.g., a mouse that models a human mycobacterial infection, wherein the mouse develops one or more granulomas comprising human immune cells. A mouse that comprises a human hematopoietic malignancy that originates from an early human hematopoietic cells is described, e.g., a myeloid leukemia or a myeloproliferative neoplasia.
Type:
Grant
Filed:
October 4, 2010
Date of Patent:
September 24, 2013
Assignees:
Regeneron Pharmaceuticals, Inc., Yale University, Institute for Research in Biomedicine
Inventors:
Sean Stevens, Andrew J. Murphy, Richard Flavell, Elizabeth Eynon, Jorge Galan, Tim Willinger, Markus Manz, Anthony Rongvaux, George D. Yancopoulos
Abstract: Provided herein are non-human animal models and related methods useful for the identification, characterization, and analysis of the effects of environmental stimuli on the development and progression of pathological conditions. The environmental stimuli can include, but are not limited to, exposure to tobacco (e.g., cigarette, etc.) smoke. Exemplary pathological conditions include, but are not limited to, atherosclerosis, other cardiovascular disease (CVD), and the like. Also provided herein are non-human animal models and related methods useful for the identification, characterization, and analysis of pharmaceutical compounds, compositions, and/or formulations that can be used to prevent or treat a given pathological condition brought on by exposure to a given environmental condition.
Abstract: A method of determining the phase of an estrous cycle that a mammal is in at a given time that a biological sample is obtained from the mammal is provided. The biological sample obtained from the mammal is combined with a flavonol and an anthocyanin and/or iodine on, or which had been stored on and subsequently removed from, a silane-based surface to provide a color response. The estrus phase of the estrous cycle has a corresponding color response that is distinguishable from the color response of each other phase of the estrous cycle to an unaided human eye. The corresponding color response is correlated to the estrus phase of the estrous cycle.
Abstract: The invention relates to antibody compositions and use of the composition to detect disease processes associated with elaboration of proteases. The reagents are directed to assessing an IgG breakdown product that is the result of such proteolytic cleavage. The invention further relates to the use of a therapeutic immunospecific for IgG protease cleavage products to restore effector function to antibody compositions that are subject to protease cleavage.
Type:
Application
Filed:
March 14, 2013
Publication date:
September 12, 2013
Applicant:
JANSSEN BIOTECH INC.
Inventors:
Robert Jordan, David Knight, Randall Brezski, Mary Ryan, Diane Petrone
Abstract: The present invention provides an agent, in particular a peptide, of formula A, comprising an amino acid sequence X1-X2-X3-X4-X5-X6 (SEQ ID NO 1) wherein X1 can be phenylalanine, isoleucine or tryptophan; X2 can be leucine or phenylalanine or alanine; X3 can be tyrosine or valine; X4 can be leucine, phenylalanine or isoleucine; 10 X5 can be phenyalanine or alanine; and X6 can be valine, arginine or tyrosine, or a fragment or variant of the peptide, wherein said peptide fragment or variant is capable of specifically binding to haemagglutinin, to inhibit the binding of a virus having haemagglutinin on its surface, for use in the treatment of a virus, for example influenza.
Type:
Application
Filed:
July 28, 2011
Publication date:
August 8, 2013
Inventors:
Anthony Nash, Bernadette Dutia, Mark Stevens
Abstract: A method induces cancer, such as ovarian cancer, in primates for testing of therapeutic treatments and preclinical research and development. A nanoparticle delivers plasmid DNA encoding oncogenes and siRNAs for tumor suppressor genes. For example, a biocompatible polymer, chitosan, is complexed with three plasmids including one that carries the cDNA encoding RAS oncogene and two plasmids encoding siRNAs for two tumor supressor genes p53 and Rb. Laproscopic delivery of these nanoparticles to the ovaries of non-human primates causes ovarian carcinoma, which is detected one month after delivery of the nanoparticles.
Abstract: A method for engineering and utilizing large DNA vectors to target, via homologous recombination, and modify, in any desirable fashion, endogenous genes and chromosomal loci in eukaryotic cells. These large DNA targeting vectors for eukaryotic cells, termed LTVECs, are derived from fragments of cloned genomic DNA larger than those typically used by other approaches intended to perform homologous targeting in eukaryotic cells. Also provided is a rapid and convenient method of detecting eukaryotic cells in which the LTVEC has correctly targeted and modified the desired endogenous gene(s) or chromosomal locus (loci) as well as the use of these cells to generate organisms bearing the genetic modification.
Type:
Grant
Filed:
June 20, 2011
Date of Patent:
August 6, 2013
Assignee:
Regeneron Pharmaceuticals, Inc.
Inventors:
Andrew J. Murphy, George D. Yancopoulos
Abstract: The present invention relates to a Drosophila in vitro system which was used to demonstrate that dsRNA is processed to RNA segments 21-23 nucleotides (nt) in length. Furthermore, when these 21-23 nt fragments are purified and added back to Drosophila extracts, they mediate RNA interference in the absence of long dsRNA. Thus, these 21-23 nt fragments are the sequence-specific mediators of RNA degradation. A molecular signal, which may be their specific length, must he present in these 21-23 nt fragments to recruit cellular factors involved in RNAi. This present invention encompasses these 21-23 nt fragments and their use for specifically inactivating gene function. The use of these fragments (or chemically synthesized oligonucleotides of the same or similar nature) enables the targeting of specific mRNAs for degradation in mammalian cells, where the use of long dsRNAs to elicit RNAi is usually not practical, presumably because of the deleterious effects of the interferon response.
Type:
Application
Filed:
March 14, 2013
Publication date:
August 1, 2013
Applicants:
Max-Planck-Gesellschaft zur Forderung der Wissenschaften E.V., University of Massachusetts, Whitehead Institute for Biomedical Research, Massachusetts Institute of Technology
Inventors:
Max-Planck-Gesellschaft zur Forderung der Wissenschaften E.V., Massachusetts Institute of Technology, Whitehead Institute of Biomedical Research, University of Massachusetts
Abstract: It is intended to provide a tool, a procedure and so on which are useful in developing a therapeutic strategy efficacious in inhibiting or overcoming the resistance against a CD20-directed molecular-targeted drug. Thus, a CD20-negatively converted B-cell malignant lymphocyte cell line is provided. Also, a model animal indicating the pathological conditions of CD20-negatively converted B-cell malignant lymphocyte is provided. Further, a method of screening a substance, which is efficacious against CD20-positive B-cell malignant lymphocyte or CD20-negatively converted B cell malignant lymphocyte, is provided. Furthermore, a drug against CD20-positive B-cell malignant lymphocyte or CD20-negatively converted B-cell malignant lymphocyte, which is characterized by being used together with a CD20-directed molecular-targeted drug, is provided. In one embodiment, a DNA methylase inhibitor or a histone deacetylase inhibitor is employed as the active ingredient.
Type:
Grant
Filed:
September 21, 2007
Date of Patent:
July 30, 2013
Assignee:
National University Corporation Nagoya University
Abstract: The present invention is directed to a method of selecting animals that are genetically resistant to one or more intestinal parasite infections by testing mucus samples for the presence of an antibody against one or more of said intestinal parasites and segregation and selecting the animals that test positive. The animals that test negative are less parasite resistant and can be subjected to parasite management regimes.
Type:
Application
Filed:
December 27, 2012
Publication date:
July 25, 2013
Inventors:
Richard John Shaw, Merie Christine Cannon, Sarah Margaret Rosanowski, Mary Wheeler, Christopher Anthony Morris
Abstract: The present invention relates to the field of transgenic animal models and more particularly the animal models of Alzheimer's disease. The invention relates to a transgenic animal expressing a multimutated form of presenilin 1 and allowing an apoptotic phenomenon to be detected in a renewable peripheral tissue.
Type:
Grant
Filed:
September 22, 2000
Date of Patent:
July 23, 2013
Assignee:
Aventis Pharma S.A.
Inventors:
Anne Eckert, Walter Muller, Christian Czech, Laurent Pradier, Gunter Tremp
Abstract: The present invention relates to FGFR4 antibodies including fragments or derivatives thereof and the polynucleotides encoding the antibodies. Expression vectors and host cells comprising the polynucleotides are provided. Further, the invention refers to pharmaceutical compositions comprising the FGFR4 antibodies and methods for the treatment, prevention or diagnosis of disorders associated with FGFR4 expression.
Abstract: This disclosure is particularly directed to arthropodal compositions in the form of capsules containing an active arthropod agent, more particularly to capsules containing an active arthropod agent and methods of making and using the same. The active arthropod agent may be an insect repellent and/or an insecticide agent.
Abstract: The present invention provides compositions for RNA interference and methods of use thereof. In particular, the invention provides small interfering RNAs (siRNAs) having modification that enhance the stability of the siRNA without a concomitant loss in the ability of the siRNA to participate in RNA interference (RNAi). The invention also provides siRNAs having modification that increase targeting efficiency. Modifications include chemical crosslinking between the two complementary strands of an siRNA and chemical modification of a 3? terminus of a strand of an siRNA. Preferred modifications are internal modifications, for example, sugar modification, nucleobase modification and/or backbone modifications. Such modifications are also useful, e.g., to improve uptake of the siRNA by a cell. Functional and genomic and proteomic methods are featured. Therapeutic methods are also featured.
Abstract: The invention relates to a multiwell system, characterized that said multiwell system having at least 3 wells, wherein said wells have a volume between 0.125 and 4.0 mm3.
Type:
Application
Filed:
July 6, 2011
Publication date:
July 4, 2013
Applicant:
UNIVERSITEIT TWENTE
Inventors:
Gustavo Andres Higuera, Lorenzo Moroni, Clemens Antoni van Blitterswijk
Abstract: The invention relates to transgenic aquatic animals, particularly the clawed frog and the zebra fish and cells derived therefrom, characterized in comprising at least one expression cassette with a regulatory DNA sequence selected from the response elements to nuclear hormone receptors, particularly TRE, connected in a functional manner downstream of a DNA segment coding for a marker protein such as luciferase or GFP. The invention further relates to methods using the transgenic cells and animals according to the invention for the identification of endocrine disrupters in the environment.
Type:
Grant
Filed:
May 27, 2003
Date of Patent:
July 2, 2013
Assignees:
Centre National de la Recherche Scientifique (CNRS), The Museum National d'Histoire Naturelle
Abstract: Disclosed are embryonic stem cells and motor neurons derived from mice carrying transgenic alleles of the normal or mutant human SOD1 gene. Also disclosed are in vitro systems employing such SOD1 transgenic motor neurons for the study of neural degenerative disease.
Type:
Grant
Filed:
April 15, 2009
Date of Patent:
June 25, 2013
Assignee:
President and Fellows of Harvard College
Abstract: The present invention provides mouse models for Pompe disease and methods of using the same to test agents that may be effective in the treatment of Pompe disease.
Abstract: The invention relates to the fields of molecular biology, medicine, virology and vaccine development. Because the different forms of the presently available vaccines all have their specific drawbacks, there is a need for alternative vaccine strategies. The current invention provides means and methods for such alternative vaccine strategies.
Type:
Application
Filed:
March 7, 2011
Publication date:
May 30, 2013
Applicant:
ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM
Abstract: The present invention features a non-human animal model that is susceptible to infection by human hepatotrophic pathogens, particularly human hepatitis C virus (HCV). The model is based on a non-human, immunocompromised transgenic animal having a human-mouse chimeric liver, where the transgene provides for expression of a urokinase-type plasminogen activator in the liver. The invention also features methods for identifying candidate therapeutic agents, e.g., agents having antiviral activity against HCV infection. The animals of the invention are also useful in assessing toxicity of various agents, as well as the activity of agents in decreasing blood lipids.
Type:
Grant
Filed:
May 30, 2012
Date of Patent:
May 21, 2013
Assignee:
KMT Hepatech, Inc.
Inventors:
Norman M. Kneteman, D. Lorne Tyrrell, David Frederick Mercer
Abstract: The invention relates to the use of CXCL5 as a marker for assessing hormone escape in prostate cancer cells. The invention further provides diagnostic methods and kits for assessing hormone escape in prostate cancer cells, and CXCL5 antagonists for use in the treatment or prevention of prostate cancer and/or hormone escape in prostate cancer.
Type:
Application
Filed:
April 19, 2011
Publication date:
April 25, 2013
Inventors:
Gwendal Lazennec, David Vindrieux, Brigitte Madly
Abstract: The present invention provides manufacturing processes for biological replication of undifferentiated plant and animal cells and tissue in a weightless condition, including those systems used in current stem cell research and development and use of undifferentiated parenchyma in plants. The present invention further provides methods for adapting plants and animals to survive outside their native environments. In particular, undifferentiated cells from plants or animals are replicated under weightless conditions in which cell replication or proliferation is accelerated and sustained. Under such conditions, the undifferentiated cells can be “forced” to express sets of genes useful for survival in particular environmental conditions. In this manner, cells surviving prolonged exposure to specific environmental conditions can be selected for and cultivated to produce an organism adapted to that particular environment in an accelerated manner.
Abstract: The present invention discloses a method for modulating the quality of a selected phenotype that is displayed by an organism or part thereof and that results from the expression of a polypeptide-encoding polynucleotide by replacing at least one codon of that polynucleotide with a synonymous codon that has a higher or lower preference of usage by the organism or part thereof to produce the selected phenotype than the codon it replaces. The present invention is also directed to the use of a codon-modified polynucleotide so constructed for modulating the quality of a selected phenotype displayed by an organism or part thereof.
Abstract: The present invention relates to methods of modulating traits, particularly production traits, in avians such as chickens. In particular, the invention relates to the in ovo delivery of a dsRNA molecule, especially siRNAs, to modify production traits in commercially important birds.
Type:
Application
Filed:
September 4, 2012
Publication date:
March 14, 2013
Applicants:
Commonwealth Scientific and Industrial Research Organisation, AUSTRALIAN POULTRY CRC PTY LTD
Inventors:
Timothy James DORAN, Robert John MOORE, John William LOWENTHAL, Craig Allen SMITH, Andrew Henrik SINCLAIR
Abstract: It is intended to provide a simple normal-tension glaucoma model capable of spontaneously, age-dependently and surly developing conditions similar to symptoms of normal-tension glaucoma which occurs more frequently in elder people, and a method of evaluating therapeutic effect on normal-tension glaucoma whereby a drug useful in treating and diagnosing can be conveniently screened by using the normal-tension glaucoma model. A normal-tension glaucoma model comprising a nonhuman mammal, which is deficient in a transcriptional regulator NF-?Bp50 and thus spontaneously develops the normal-tension glaucoma symptom age-relatedly, an organ or a tissue thereof or cells collected from any of the same.
Abstract: Disclosed are polynucleotides and methods for expressing light activated proteins in animal cells and altering an action potential of the cells by optical stimulation. The disclosure also provides animal cells and non-human animals comprising cells expressing the light-activated proteins.
Type:
Application
Filed:
March 17, 2011
Publication date:
January 17, 2013
Inventors:
Karl Deisseroth, Feng Zhang, Viviana Gradinaru
Abstract: A flow cytometer system for sorting haploid cells, specifically sperm cells, may include an intermittingly punctuated radiation emitter, such as a pulsed laser. Embodiments include a beam manipulator and even split radiation beams directed to multiple nozzles. Differentiation of sperm characteristics with increased resolution may efficiently allow differentiated sperm cells to be separated at higher speeds and even into subpopulations having higher purity.
Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a Hepatitis B Virus gene. The invention also relates to a pharmaceutical composition comprising the dsRNA or nucleic acid molecules or vectors encoding the same together with a pharmaceutically acceptable carrier; methods for treating diseases caused by Hepatitis B Virus infection using said pharmaceutical composition; and methods for inhibiting the expression of a Hepatitis B Virus gene in a cell.
Type:
Application
Filed:
June 28, 2012
Publication date:
January 3, 2013
Applicant:
ARROWHEAD RESEARCH CORPORATION
Inventors:
Daniel J. Chin, Jochen Deckert, Markus Hossbach, Matthias John
Abstract: Compositions for nematode growth and methods for using the same for nematode viability are described. The compositions contain a solid matrix material that is dispersed in a liquid medium. The solid matrix can be immersed, bathed, and/or interspersed in a liquid medium to form a composite culture that is capable of maintaining or growing nematodes at unexpectedly high densities and/or with nominal stress pathway activity. Other embodiments are described.
Type:
Application
Filed:
June 22, 2012
Publication date:
December 27, 2012
Inventors:
Christopher E. Hopkins, John P. Manfredi
Abstract: The present invention relates to animal model systems comprising a chimera between an avian embryo and a mammalian organism. Specifically, chimeric model systems comprising normal, diseased or genetically transformed mammalian cells and tissues transplanted into avian embryos, and uses thereof for in vivo testing of drugs and therapeutic modalities are disclosed.
Type:
Grant
Filed:
June 28, 2005
Date of Patent:
December 4, 2012
Assignees:
Bar Ilan University, Medical Research Fund of Tel-Aviv Sourasky Medical Center
Inventors:
Ron Goldstein, Tamar Tennenbaum, Varda Deutsch
Abstract: Laboratory-selected colonies of western corn rootworm exhibiting tolerance to maize containing event DAS-59122-7 are described. Further, methods for various uses of these resistance western corn rootworm colonies are also described, including development of negative cross-resistance strategies and improved resistance management strategies.
Type:
Grant
Filed:
October 3, 2008
Date of Patent:
December 4, 2012
Assignee:
Pioneer Hi-Bred International, Inc.
Inventors:
Rachel Binning, Stephen Lefko, Timothy Nowatzki, Stephen Thompson
Abstract: Methods and compositions are presented for the administration of transposon-based vectors to an animal or human to provide gene therapy to the animal or human.
Type:
Application
Filed:
July 31, 2012
Publication date:
November 22, 2012
Applicants:
TransGenRx, Inc., The Board of Supervisors of Louisiana State Univ. and Agricultural and Mechanical College
Inventors:
Richard Cooper, Frederick M. Enright, William C. Fioretti
Abstract: The present invention provides tissues derived from animals, which lack any expression of functional alpha 1,3 galactosyltransferase (alpha-1,3-GT). Such tissues can be used in the field of xenotransplantation, such as orthopedic reconstruction and repair, skin repair and internal tissue repair or as medical devices.
Abstract: A transgenic non-human animal, in particular a transgenic mouse encoding A? peptide proteins, which have been implicated in A? peptide-related diseases. Cells and cell lines comprising transgenes encoding for A? peptide. Methods and compositions for evaluating agents that affect A? peptide, for use in compositions for the treatment of A? peptide-related diseases.
Type:
Grant
Filed:
September 12, 2008
Date of Patent:
October 9, 2012
Assignee:
Probiodrug AG
Inventors:
Stephan Schilling, Holger Cynis, Hans-Ulrich Demuth, Wolfgang Jagla, Sigrid Graubner
Abstract: The present invention relates, in general, to gene expression and, in particular, to a method of inhibiting the expression of a target gene and to constructs suitable for use in such a method.
Abstract: This invention relates to methods for making immune compatible tissues and cells for the purpose of transplantation and tissue engineering, using the techniques of nuclear transfer and cloning. Also encompassed are methods for determining the effect on immune compatibility of expressed transgenes and other genetic manipulations of the engineered cells and tissues.